Nebivolol in Patients With Systolic Stage 2 Hypertension
(NEB-MD-20 Trial)
Recruiting in Palo Alto (17 mi)
+35 other locations
Age: 18 - 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Waitlist Available
Sponsor: Forest Laboratories
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The primary object of this study is to evaluate the efficacy and safety of 6 weeks of nebivolol monotherapy compared with placebo in patients with systolic stage 2 hypertension.
Research Team
MS
Manfred Stapff, MD, PhD
Principal Investigator
Forest Research Institute, a Subsidiary of Forest Laboratories Inc.
Eligibility Criteria
Inclusion Criteria
male of female, 18 to 64 years of age at screening
mean seated heart rate at least 60 bpm
diagnosed systolic stage 2 hypertension
See 1 more
Treatment Details
Interventions
- Nebivolol (Beta Blocker)
- Placebo (Drug)
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: 1Experimental Treatment1 Intervention
Group II: 2Placebo Group1 Intervention
Nebivolol is already approved in Canada for the following indications:
Approved in Canada as Nebivolol for:
- Hypertension
- Heart failure
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Forest Investigative Site 007Auburn, ME
Forest Investigative Site 011Baltimore, MD
Forest Investigative Site 012Hickory, NC
Forest Investigative Site 013Charleston, SC
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Forest Laboratories
Lead Sponsor
Trials
338
Patients Recruited
89,200+
Founded
1956
Headquarters
New York City, USA
Known For
Depression Medications
Top Products
> Celexa, Lexapro, Namenda, Savella